- Home
- ADXN vs GLMD Comparison
ADXN vs GLMD Comparison
Compare ADXN & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- GLMD
- Stock Information
- Founded
- ADXN 2002
- GLMD 2000
- Country
- ADXN Switzerland
- GLMD Israel
- Employees
- ADXN N/A
- GLMD N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- GLMD Health Care
- Exchange
- ADXN Nasdaq
- GLMD Nasdaq
- Market Cap
- ADXN 8.5M
- GLMD 8.0M
- IPO Year
- ADXN N/A
- GLMD 2014
- Fundamental
- Price
- ADXN $8.86
- GLMD $1.39
- Analyst Decision
- ADXN
- GLMD Hold
- Analyst Count
- ADXN 0
- GLMD 1
- Target Price
- ADXN N/A
- GLMD N/A
- AVG Volume (30 Days)
- ADXN 23.3K
- GLMD 71.0K
- Earning Date
- ADXN 11-21-2025
- GLMD 11-13-2025
- Dividend Yield
- ADXN N/A
- GLMD N/A
- EPS Growth
- ADXN N/A
- GLMD N/A
- EPS
- ADXN N/A
- GLMD N/A
- Revenue
- ADXN $210,347.00
- GLMD N/A
- Revenue This Year
- ADXN $86.57
- GLMD N/A
- Revenue Next Year
- ADXN N/A
- GLMD N/A
- P/E Ratio
- ADXN N/A
- GLMD N/A
- Revenue Growth
- ADXN N/A
- GLMD N/A
- 52 Week Low
- ADXN $6.51
- GLMD $1.15
- 52 Week High
- ADXN $12.05
- GLMD $4.81
- Technical
- Relative Strength Index (RSI)
- ADXN 48.84
- GLMD 44.53
- Support Level
- ADXN $8.53
- GLMD $1.33
- Resistance Level
- ADXN $10.55
- GLMD $1.44
- Average True Range (ATR)
- ADXN 0.72
- GLMD 0.09
- MACD
- ADXN -0.03
- GLMD -0.01
- Stochastic Oscillator
- ADXN 9.86
- GLMD 18.72
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.